PBM Patient-Level Recall Communication – Moxifloxacin Ophthalmic Solution: Recall Due to Discoloration

Jan 31, 2020 | Optometry HQ Announcements



  • Facility  Director  (or  physician  designee):  Forward this document to the Facility Chief of Staff (COS).
  • Facility COS (and Chief Nurse Executives): Forward this document to all appropriate providers who prescribe this agent (e.g., primary care providers, eye care specialists, and pharmacy staff, including contract providers, etc.). In addition, forward to the Associate Chief of Staff (ACOS) for Research and Development (R&D). Forward to other VA employees as deemed appropriate.
  • ACOS for R&D: Forward this document to Principal Investigators (PIs) who have authority to practice at the facility and to your respective Institutional Review Board (IRB).
  • Note: No feedback is required for provider notification, so providers are not required to log in to the website.


Chief of Pharmacy: Within 10 business days of issue (due 2/13/2020), communicate to PBM/VAMedSAFE that all patient notification actions have been completed via the VHA Alerts and Recalls Website: The current recall is posted as PRO-14864 [Moxifloxacin Ophthalmic Solution: Recall Due to Discoloration].

Note: VISN level suspense is not needed; per VHA Directive 1069 (, PBM will monitor compliance and non-responders will be reported to the Deputy Under Secretary for Health for Operations and Management for follow-up.

Instructions for Pharmacy Chiefs on how to close out the recall can found at the following:

Instructions for Pharmacy To Close Out Patient Level Recall

Moxifloxacin Ophthalmic Solution Recall Due to Discoloration_National PBM Patient-Level Recall Communication_FINAL_013020